Adventrx 8-K 11-02-2004
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) November 2, 2004
ADVENTRX Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
|
001-32157
(Commission File Number) |
|
84-1318182
(IRS Employer Identification No.) |
6725 Mesa Ridge Road, Suite 100
San Diego, California 92121
(Address of principal executive offices) (Zip Code)
(858) 552-0866
(Company’s telephone number, including area code)
Item 8.01. Other Events.
|
On November 2, 2004, the Company announced certain developments regarding its CoFactor Phase II trial and current plans regarding certain regulatory filings. |
|
The press release issued by the Company on November 2, 2004 with respect to these matters is included with this report as an exhibit. |
Item 9.01. Financial Statements and Exhibits.
| (c) |
The exhibit list required by this item is incorporated by reference to the Exhibit Index filed as part of this report. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
ADVENTRX Pharmaceuticals, Inc. |
| |
|
| |
|
| |
By: |
/s/ Steven M. Plumb |
|
| |
|
Name: Steven M. Plumb |
| |
|
Title: Chief Financial Officer |
| |
|
|
| |
|
November 3, 2004 |
EXHIBIT INDEX
|
Exhibit |
Description |
| |
|
|
99.1 |
Press Release of the Company dated November 2, 2004. |